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Structured Abstract 
 
Background: Stroke is currently the 4
th
 leading cause of death in the United States. After a 
systematic review in 1996, the USPSTF concluded that the evidence was insufficient to 
recommend for or against screening of asymptomatic people for carotid artery stenosis (CAS) 
using auscultation for carotid bruit during physical exam. Using the reference standard of 70-
99% stenosis on carotid angiogram, they determined the sensitivity and specificity of a carotid 
bruit to be 63-76% and 61-76% respectively for identifying CAS of this degree. 
Purpose: To examine the evidence since the 1996 USPSTF review on accuracy of auscultation 
for carotid bruit as a screening test for CAS and subsequent stroke outcomes to provide accuracy 
data and help afford better guidance on the utility of this means of screening for CAS in 
asymptomatic patients in the general population. 
Data Sources: MEDLINE search (January 1996-present), recent randomized controlled trials 
(RCTs), cohort studies, and diagnostic accuracy studies, reference lists of retrieved articles. 
Study Selection: English language studies were selected to answer the questions: (KQ1) What is 
the accuracy of auscultation for carotid bruit to predict fatal or nonfatal ischemic stroke or TIA?  
(KQ2) What is the accuracy of auscultation for carotid bruit to detect potentially clinically 
important CAS (60% to 99%)? Study types were RCTs or cohort studies of asymptomatic 
patients at least 19 years of age, from which data on cerebrovascular outcomes could be 
extracted. Also they could be diagnostic accuracy studies comparing auscultation for carotid 
bruit to the gold standard of angiography in asymptomatic patients at least 19 years of age. 
Data Synthesis: There were no RCTs of screening for CAS by auscultation for carotid bruit. 
Two included cohort studies showed the sensitivity and specificity of carotid bruit to identify 
subsequent stroke in asymptomatic patients to be 9.1-13.4% and 93.75-96.7% respectively with 
  
false-negative rates of 86.6-90.9%. No studies met inclusion for KQ2 due to improper gold 
standard, but 2 cohort studies and a systematic review using the reference of duplex ultrasound, 
the sensitivity and specificity for identifying CAS ≥ 60% were 56.25-57.5% and 80-98%.    
Limitations: There were no RCTs of screening for CAS to answer KQ1 and the included cohort 
studies were conducted in selected populations with diabetes or isolated systolic hypertension. 
These only focused on stroke without assessing the outcome of TIA. No accuracy studies met 
inclusion for KQ2 that used the gold standard of angiography. The quality of included studies 
was only fair on average. 
Conclusions: The sensitivity and specificity of auscultation for carotid bruit are low and exhibit 
poor accuracy for a screening test. Such low values would result in high false-positive and false-
negative rates, both for identifying CAS as well as subsequent stroke in the asymptomatic 
population. Inadequate certainty of the benefit of screening for CAS in the general asymptomatic 
population, lack of a reliable means to delineate a more distinct group to screen in, and the poor 
accuracy of auscultation for carotid bruit in the primary care setting makes it difficult to consider 
widespread use of this screening test in the general population. Until we know with reasonable 
certainty that such screening leads to reduced strokes and better understand how to delineate the 
best group of people to screen in, I do not recommend the use of auscultation for carotid bruit in 
the primary care setting as a screening test for CAS and future cerebrovascular outcomes in 
asymptomatic patients. 
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Accuracy of Auscultation for Carotid Bruit in Asymptomatic Patients to Screen for 
Carotid Artery Stenosis and Stroke Outcomes: a Systematic Review 
Introduction: 
 Stroke is currently the 4
th
 leading cause of death in the United States (1). Approximately 
6.8 million Americans over 20 years of age have experienced a stroke at some point in the past. 
The prevalence of past stroke is estimated to be about 2.8% (2). This prevalence estimate is 
derived by taking prevalence results of the health interview portion of the National Health and 
Nutrition Examination Survey (NHANES) from 2007-2010 and applying these figures to 
national Census population estimates for 2010. Thus, this relies heavily on national survey data. 
Each year approximately 785,000 Americans experience a stroke, with 610,000 of these people 
experiencing a first stroke. This translates into an average of one person suffering a stroke in the 
United States every 40 seconds (2). These are extrapolations to the current US population from 
data of various studies including the Framingham Heart study and the Cardiovascular Health 
Study.  
The consequences of stroke are often quite devastating. A recent study showed stroke to 
have a mortality rate of 4.5% due to the acute event or within the initial 30 day period following 
the event; 20 year mortality rate is as high as 27% for ischemic stroke in adults of age 18 to 50 
years (3). Stroke accounted for nearly 1 out of every 19 deaths in the US based on data from 
2009 (4). Beyond just mortality, stroke is also the leading cause of severe long-term disability in 
the United States, frequently resulting in hemiparesis, severe cognitive defects, and significant 
dependence in activities of daily living among other consequences (5, 6). Therefore, it is clear 
that the burden of stroke in our country is quite substantial.  
However, there has been improvement as the current stroke mortality rate represents an 
almost 70 percent reduction since 1950 and a decline of nearly 37% since 1999 (2, 4). A great 
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deal of this has been attributed to better control of important risk factors such as hypertension 
and tobacco use in the population.  
More recently, specifically since the publication of the Asymptomatic Carotid Surgery 
Trial (ACST) in 2004, there has been increased use of carotid endarterectomy (CEA) as well as 
carotid angioplasty and stenting (CAAS) as revascularization techniques to treat patients whose 
strokes may be attributable to carotid artery stenosis (CAS). Major randomized controlled trials 
(RCTs) have shown that CEA effectively reduces stroke in symptomatic people with severe 
carotid artery stenosis (7, 8). In this case symptomatic is defined as those who have previously 
suffered a transient ischemic attack (TIA) or stroke. Thus there is benefit to evaluating and 
treating these symptomatic patients. However, even with the results of the ACST, there is still 
much less clarity when it comes to asymptomatic patients who have had no previous 
cerebrovascular events or significant neurologic symptoms referable to the carotid artery. 
Though carotid artery stenosis can be identified in asymptomatic patients as well, it is not clear 
whether screening them for CAS and treating with revascularization such as CEA or CAAS leads 
to reduction in stroke (9). 
 After completing a systematic review on the topic of screening asymptomatic people for 
CAS in 1996, the USPSTF concluded that the evidence was insufficient to recommend for or 
against screening of asymptomatic people for CAS using auscultation for carotid bruit during 
physical exam or by carotid ultrasound (10). This was based partly on new evidence at the time 
from the Asymptomatic Carotid Artery Study (ACAS), a large RCT involving 1662 
asymptomatic patients with carotid stenosis of 60 percent or greater. Though this trial showed 
some benefit in the surgical group with relation to stroke incidence and death compared to the 
control group over the course of 2.7 years of follow-up, these results depended significantly on 
Watford 3 
 
the rate of perioperative complications involved. The interventions in this trial were performed in 
centers by surgeons with very low complication rates. There was also very little information 
available at the time on what the complication rates for CEA were in the general population. 
Thus the generalizability of the results from the ACAS trial to the general public was unclear, 
making it difficult to determine if screening asymptomatic patients for CAS and then treating 
them yields benefit in this population. These reasons were the major contributors to the 
USPSTF’s 1996 conclusion that there was insufficient evidence to recommend for or against 
screening (10).  
 Specifically concerning auscultation for carotid bruit, the USPSTF found this to be an 
imperfect screening test for CAS with ample inter-observer variation among clinicians 
performing the test. Using stenosis of 70-99% on angiogram as the reference, they also found 
this test to have poor sensitivity and specificity; 63-76% and 61-76% respectively (10). 
Since the 1996 review more data has emerged and further studies have been conducted 
attempting to investigate the role of screening and treatment for CAS in asymptomatic patients as 
well as complication rates from treatment in community and academic settings. This includes the 
ACST, one of the largest multicenter RCTs on the topic published in 2004 that involved 3120 
asymptomatic patients with CAS of 60 percent or greater (7). Due to this new evidence the 
USPSTF conducted an update in 2007 to their previous review on screening for CAS. However, 
due to their findings in 1996 and a paucity of new evidence on the topic, the USPSTF decided 
not to focus on auscultation for carotid bruit during physical exam as a screening tool for this 
2007 update (9). After reviewing the new evidence in 2007, the task force concluded that 
screening would result in considerable false-positives leading to harms from confirmatory testing 
or unnecessary surgeries, namely carotid endarterectomy. These harms outweighed the potential 
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benefit of preventing stroke from these procedures, leading to the USPSTF’s updated 
recommendation not to screen for asymptomatic CAS in the adult population (9).   
Relevance of Screening for CAS and its Related Outcomes 
 Effective screening tools are designed to identify individuals in a population that may be 
at increased risk for a disease or disorder that would otherwise go unrecognized until a later time. 
If identified early through screening, these individuals may or may not be able to receive early 
treatment or intervention that could reduce morbidity and/or mortality from the disease or 
disorder in question. The use of screening is especially useful for diseases that have an especially 
detrimental course if identified at later stages as opposed to catching it earlier. Based on 
guidelines drafted by the World Health Organization (WHO), screening should only be applied if 
the disorder in question is an important health problem and there is a treatment for the disorder 
(11). Also the magnitude of benefits from screening should be weighed against the magnitude of 
harms to determine the net benefit that would arise from a specific screening protocol (12). 
Clearly stroke is an important health problem with seriously detrimental consequences if not 
prevented. Therefore, it would be advantageous to identify those people at risk for stroke prior to 
the actual event so that they can be treated early and possibly avoid such a detrimental event. As 
CAS is a risk factor for stroke and accounts for approximately 10-15% of strokes in the general 
population based on crude extrapolation from stroke prevalence numbers by type and 
epidemiological data, screening for this is important to potentially avoid the serious 
consequences of stroke (9). Screening tests require confirmation using further testing that is more 
certain but may also be more time-consuming, invasive, expensive, and may cause harms. Thus, 
initial screening tests are often simpler, less invasive, and require less time to administer and 
evaluate. Therefore, screening for CAS by auscultation for carotid bruit during physical exam 
Watford 5 
 
may be suitable as a screening test because it is very inexpensive and is a simple, non-invasive 
test that is quick to administer. 
 This review is an adjunct to a review by the USPSTF to update their previous 2007 
review of screening for CAS. The review will revisit auscultation for carotid bruit as a screening 
test for CAS as in the 1996 review, with angiography as the confirmatory testing. It draws upon 
the 1996 and 2007 recommendations and looks at the evidence on accuracy of carotid bruit 
auscultation in CAS screening. I will investigate the focused question of what is the accuracy of 
auscultation for carotid bruit to predict fatal or nonfatal ischemic stroke or TIA ipsilateral to 
CAS.  As another key question, I will also investigate the accuracy of this screening method to 
detect potentially clinically important CAS (60-99%). I am focusing on accuracy or the ability of 
auscultation to identify actual stroke outcomes as well as CAS of 60-99% as opposed to 
reliability or the ability of auscultation measurements to be reproducible under the same 
conditions from one measurement to the next. 
It is important to note that 60-99% stenosis is the range that is generally considered in 
several major studies and most guidelines to represent clinical significance for ischemic 
outcomes and also the point at which revascularization procedures such as CEA are indicated. 
However, the evidence does not clearly show that the 60% lower bound actually designates the 
point at which risk of ischemic outcome in individuals increases greatly above that of others in 
the general population with stenosis values slightly below or above this cutoff point. In fact the 
most significant increase in risk has actually been noted at ranges above 70%, which is also the 
cutoff where the most benefit is seen from endarterectomy based on symptomatic patients in the 
North American Symptomatic Carotid Endarterectomy Trial (NASCET) as well as in 
asymptomatic patients in the ACST (13, 14). Nonetheless, this review will focus on the range of 
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60-99% to represent clinically important CAS based on its frequent use in the scientific 
literature. This review will systematically take into account the newly available evidence since 
the previous USPSTF reviews with the hope of providing healthcare providers with updated 
guidance on the utility of auscultation for carotid bruit as an effective screening test for 
predicting cerebrovascular events from CAS.   
Background: 
What is Carotid Artery Stenosis? 
 
 Carotid artery stenosis is defined as the pathologic narrowing of the lumen of the 
extracranial carotid arteries due to atherosclerotic disease. The relationship between the degree 
of narrowing and the risk of stroke has not been clearly demonstrated and this relationship is 
further complicated largely because many patient factors others than the degree of narrowing 
affect the risk of stroke. A clinically significant degree of carotid stenosis may be very different 
in an elderly male patient with a smoking history and diabetes than it would be in a younger 
female patient with hypertension but no smoking history. Because of this uncertainty in how 
degree of carotid narrowing relates to stroke risk, there is variation in the definition of clinically 
significant CAS. Major RCTs including the ACAS and the ACST defined CAS as 60-99 percent 
while some earlier trials including the NASCET looking at symptomatic patients used 50-99 
percent. As mentioned, these studies found that the highest risk of stroke and the greatest benefit 
from treatment manifested at CAS levels of greater than 70%, though there was some modest 
benefit in those with CAS of 50-69% with a 5-year absolute risk reduction of 6.5% for ipsilateral 
stroke after treatment with CEA (13, 14).  
Prevalence and Clinical Importance of CAS in the General Population 
 
 A recent systematic review and meta-analysis published in 2009 that included 40 cross-
sectional and cohort studies dating back to 1983 found variation in prevalence figures of CAS 
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based on differences in certain demographic factors, CAS cut-off points used for identification, 
and the methods used to grade stenosis (15). This study had several limitations though, mostly 
due to a pretty large degree of heterogeneity among included studies. This especially applied to 
differences in the way patients were recruited for the various studies, which affects their 
representativeness of the general population. As mentioned, there was also variance in the 
method of measuring the degree of stenosis between the studies such as NASCET versus ECST 
methods as well as differences in response rates of participants in the different studies, with older 
patients responding less. This lends to potential selection bias and likely underestimation of 
overall prevalence rates as asymptomatic CAS is believed to be more prevalent in older 
individuals. Some of the included studies were also a bit outdated as seven of them were 
published prior to 1990. More recent prevalence estimates may differ due to changes in current 
management of CAS risk factors and use of various medications such as statins in those at risk 
for CAS and other vascular outcomes. The review included studies from US populations as well 
as from various European countries, Mexico, Japan, China, and Australia. The ages of patients 
varied amongst the studies, ranging from 18 to 101 years old. There was also variance in the sex 
distributions between the included studies. As a result there was significant variation in 
prevalence estimates across the included studies, which affects our ability to draw concrete 
conclusions from the study and generalize the findings to specific populations such as that of the 
US.  
The review findings showed a pooled prevalence of 4.8 percent (men) and 2.2 percent 
(women) for CAS greater than 50 percent stenosis in people less than age 70. In those older than 
age 70 these numbers were 12.5 percent and 6.9 percent respectively. They found that the 
prevalence of CAS increases with age in both men and women, but men of all ages have higher 
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prevalence estimates than women. The overall pooled prevalence of 70 percent or greater 
stenosis was 1.7 percent. The prevalence of this same degree of stenosis in asymptomatic people 
at least 80 years old was quite small at 3.1 percent in men and 0.9 percent in women (15, 16). 
The analysis for the most recent USPSTF recommendation on the topic estimated the prevalence 
of people with unknown CAS to be 1 percent or less in the general population and 1 percent in 
people at least 65 years of age (9). This was mainly based on data from the Framingham and the 
Cardiovascular Health Studies.  
 A clinically significant degree of CAS is considered to be the degree of stenosis that 
corresponds to a high enough increased risk of stroke, leading to a change in clinical 
management beyond that for those considered to be at baseline risk. This poses quite a challenge 
to define, especially in asymptomatic people, as the risk of stroke depends on much more than 
solely the level of carotid lumen narrowing. Several studies including the Cardiovascular Health 
Study have shown an increased risk of stroke with greater degrees of stenosis as well as multiple 
risk factors (17, 18). The majority of studies investigating CAS treatment considered clinically 
significant stenosis to be   50 or   60 percent. This difference is not a trivial one though as a 
relative cutoff point difference of 10% stenosis amongst the general population would 
encompass a huge amount of people. Essentially by setting such a cutoff point, you are treating 
what is really a continuous variable as a categorical one. Since degree of carotid stenosis is truly 
a continuous variable, there is a wide spectrum across which people in the population will fall. 
One way to picture this is on a bell curve with number of people on the y-axis and degree of 
stenosis on the x-axis. People with the very high and very low degrees of stenosis would be at 
the respective extremes with all others falling between these extremes. The bulk of the 
population would be represented by the more intermediate stenosis values falling in the middle 
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including those with 50% and 60%, although the actual median probably falls closer to 20-30% 
depending on the ages being considered. As you follow along the curve, the drop off from a 50% 
cutoff to a 60% one encompasses a great amount of people when thinking in terms of an entire 
population. This is shown in figure 1 as the difference in the amount of people classified for 50% 
versus 60% stenosis is represented by the volume under the curve outlined by the rectangle. 
Thus, it is important to utilize a cutoff point that is supported by strong evidence of associated 
risk rather than arbitrarily selecting one based on guidelines and amending under the assumption 
that what applies to one cutoff point must also apply to a higher one, as in 50% versus 60% 
stenosis. This phenomenon is commonly known as guideline creeping.  
Figure 1: Bell Curve representation of CAS in General Population  
 
    
 
CAS-Related Stroke Burden 
 
 The percentage of strokes in the general population that are related to CAS is even less 
clear. The majority of strokes are ischemic, accounting for approximately 87 percent of all 
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(NASCET) found that as much as 45% of strokes in the territory of asymptomatic carotid arteries 
with 70-99 percent stenosis were not related to CAS (20). However, this study population was 
composed of symptomatic patients though they looked at asymptomatic carotid arteries on the 
contralateral side from previous events. From this data the USPSTF previously attempted to 
extrapolate the burden from CAS, estimating that CAS is the cause of stroke in less than 15 
percent of cases and even less in those that are asymptomatic (9). The population-attributable 
risk is thought to be 2 to 7 percent (2). The annual risk of stroke in asymptomatic patients with 
CAS has been decreasing in recent years, in large part due to the improved and higher-intensity 
medical therapy recommended in these patients (21). In such patients receiving proper medical 
therapy, recent studies including a systematic review looking at mostly hospital-based data 
estimated the risk of stroke to be less than 1 percent per year and could be as low as 0.3 percent 
per year (22, 23). Though this seems like a low percentage, one must still keep in mind the large 
number of strokes occurring in our country each year. Such a small percentage of a number as 
great as 785,000 still accounts for a substantial health burden in this population that should not 
be overlooked.  
Risk Factors for CAS 
 
 Several important risk factors for clinically significant CAS have been identified. These 
factors include smoking, hypertension, and heart disease as well as male sex and age greater than 
65 years (24-26). Smoking and heart disease are especially linked to greater risk of CAS, yet like 
the others listed, they actually only lead to small absolute increases in risk. Good studies 
demonstrate greater than double the relative risk for CAS ≥ 50% in patients from each of these 
risk factors independently. Yet when looking at the absolute risk, the increase is not very large 
with CAS risks of 4.4% for those who never smoked versus 9.5% for current smokers and 18.2% 
Watford 11 
 
for those with heart disease compared to 8% for those without heart disease (24, 26). Results 
from the Cardiovascular Health Study looking at patients with CAS ≥ 50% found even smaller 
differences in absolute risk for this degree of stenosis.  Their results showed a risk of 7% in 
current smokers vs. 4% in nonsmokers and the same absolute risks for those with history of 
coronary artery disease vs. those without respectively (27). In the same study patients with 
hypertension showed a risk of 5% compared to 3% in those without, 4% for males compared to 
5% for females, and 4% for those age 65-75 years compared to 5% for those older than 75 years 
(27). These small absolute differences in risk do not predict CAS very well and do little to 
separate patients out in terms of differences in clinical management.  
The fact that a risk factor shows incremental statistical increases in risk is not sufficient 
enough to warrant its use in clinical practice. The use of the risk factor must have real clinical 
utility so that its identification leads to changes in recommended clinical management. This often 
requires that such factors raise the risk above an agreed upon threshold that above which 
management differs from those individuals who’s risk falls below the threshold (28). So even 
with this knowledge of risk factors, we still are unable to clearly separate out the people who 
possess clinically significant CAS from those without it due to small differences in absolute risk.  
Screening for CAS 
 
 Screening for carotid artery stenosis is generally performed by auscultation for carotid 
bruits during physical examination or by noninvasive imaging of the carotid artery, most often 
by duplex ultrasound. Carotid angiography is considered the gold standard for evaluating the 
carotid arteries for stenosis but is not recommended as a screening test due to its level of 
invasiveness, expense, and associated morbidity and mortality. This review focuses on the use of 
auscultation for carotid bruit as a screening test of clinically significant CAS.  
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A carotid bruit is defined as an audible sound arising from turbulent blood flow in the 
carotid artery and often heard through auscultation with the stethoscope. Several older studies 
have found that carotid bruits in asymptomatic patients have poor predictive value of underlying 
carotid stenosis and stroke risk. These studies found that the annual incidence of stroke occurring 
ipsilateral to an asymptomatic carotid bruit is only 1-3 percent (29, 30). In one of these 
prospective studies looking at 500 patients with asymptomatic carotid bruits in a Canadian 
population, only 22.6 percent of them were found to have a carotid stenosis of 70-99 percent by 
Doppler ultrasound (29). Also results from a prospective population study of asymptomatic 
people ≥ 45 years old living in rural Evans County, Georgia showed that out of the patients with 
a clinically significant carotid stenosis of 70-99 percent, only about half of them have a bruit that 
can be detected on physical exam (31). A more recent study in elderly patients found that the 
presence of a carotid bruit translated into a risk for stroke of 1.86 per 100 patient-years compared 
to 1.21 per 100 patient years in those without bruits. This led to an unadjusted relative risk of 
1.53 and 1.29 when adjusted for risk factors over an average follow-up period of 4.2 years (32). 
This relative risk was not statistically significant after statistical analysis. Some of the poor 
predictive value of carotid bruit for detecting significant carotid stenosis in asymptomatic people 
is due to the low prevalence of such levels of stenosis in this population in the first place (33, 
34). Previous studies show that carotid bruit may be a better indicator of general atherosclerotic 
disease than of stroke risk (35, 36).   
For these reasons the USPSTF as well as the American Heart Association have 
previously recommended against the use of this screening for CAS in asymptomatic patients. 
However, many physicians still continue to employ this as part of their physical examinations in 
this patient population and often use it to inform their course of care as it is a cheap, non-
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invasive, and relatively easily-administered test. Hopefully this review of the updated evidence 
on auscultation for carotid bruit will provide accuracy data and help afford better guidance on the 
utility of this means of screening for CAS in asymptomatic patients in the general population. 
Methods: 
 
For this review I am focusing on 2 key questions (KQ). KQ1: What is the accuracy of 
auscultation for carotid bruit to predict fatal or nonfatal ischemic stroke or TIA?  KQ2: What is 
the accuracy of auscultation for carotid bruit to detect potentially clinically important CAS (60% 
to 99%)? This review is an adjunct to a review by the USPSTF to update their previous 1996 and 
2007 reviews of screening for Carotid Artery Stenosis (CAS). This focuses on auscultation for 
carotid bruit as the screening test with angiography as the confirmatory testing. An analytic 
framework was developed for this review following USPSTF methods and is shown in Figure 2.  
 KQ1: What is the accuracy of auscultation for carotid bruit to predict fatal or nonfatal 
ischemic stroke or TIA? 
 
 KQ2: What is the accuracy of auscultation for carotid bruit to detect potentially clinically 
important CAS (60% to 99%)? 
 
Figure 2. Analytic Framework for Screening for Carotid Artery Stenosis    
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Study Inclusion/Exclusion Criteria 
 For the purposes of this review I defined clinically significant CAS to be 60-99 percent 
because this is the cutoff generally used to justify use of carotid endarterectomy or carotid artery 
stenting and is consistent with that used in the ACAS trial published in 1995 and ACST trial in 
2004. However, I will not exclude studies looking at 50 percent or greater to ensure that studies 
using such a cutoff that may provide valuable accuracy information are not missed. For inclusion 
in this review, studies had to look at populations of adults who were asymptomatic for any stroke 
symptoms and are screened for CAS by auscultation for carotid bruit. Asymptomatic must 
indicate that these patients have no significant neurologic symptoms that are referable to the 
carotid artery and also no previous strokes or TIAs. Patients must also lack a history of previous 
myocardial infarctions as this is a sign of poor cardiovascular health and likely delineates a 
subgroup of higher risk patients that is not representative of the asymptomatic general 
population. Adults are considered to be people 19 years of age or older. This excludes children 
and adolescents and patients that do not speak English. Also it excludes any patients currently 
suffering from neurologic symptoms or those with a history of TIAs or stroke. I’m also 
excluding any patients undergoing coronary artery bypass graft (CABG) procedures and those 
who have received remote procedures for treatment of CAS such as CEA or CAAS and are 
undergoing surveillance for recurrent problems as these patients are not considered 
asymptomatic.  
Relevant studies must compare this included population of patients undergoing screening 
to a group of patients with similar characteristics who are not screened by auscultation for 
carotid bruit or not found to have a bruit on auscultation. The intervention of auscultation for 
carotid bruit must be performed by primary care physicians in an office setting as this is 
generally considered to be the most useful setting for this screening technique. This includes 
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cardiologists and neurologists but excludes studies examining carotid auscultation by vascular 
surgeons as they are considered more highly specialized than other physicians generally 
practicing in primary care settings. For inclusion the studies must be RCTs or cohort studies 
comparing screened versus non-screened group. For the other KQ studies must be diagnostic 
accuracy studies also evaluating auscultation for bruit with comparison to the gold standard of 
angiography. They must be published since 1996 since this is when the last USPSTF review 
examining the topic of auscultation for carotid bruit was completed. All other study types are 
excluded, including case-control studies to avoid introducing further bias including confounding, 
measurement, and selection bias (37). To better ensure that studies were performed in 
populations generalizable to the U.S., I am including only those performed in countries with a 
“very high” human development index based on the UN Development Program. This comprises 
47 countries. The predetermined inclusion and exclusion criteria are included in a PICOTTS 
table shown in Table 1. 
Table 1. PICOTTS Table 
 
 Inclusion Exclusion 
Populations Adults in the general population asymptomatic for stroke 
symptoms who are screened for CAS by auscultation for 
carotid bruit. Asymptomatic indicates they have no 
significant neurologic symptoms referable to the carotid 
artery and have no previous cerebrovascular events. 
Adults defined as 19 years or older. 
Children and 
adolescents; 
symptomatic adults 
with CAS or with 
history of TIAs, 
strokes, or MI. 
People with remote 
CEA or CAAS for 
previous stenosis 
undergoing 
surveillance. Also 
patients undergoing 
CABG or 
myocardial 
revascularization. 
Intervention Auscultation for carotid bruit by primary care physicians 
in office setting as screening tool for clinically important 
CAS necessitating referral for duplex ultrasonography. 
Include cardiologists and neurologists in clinic setting. 
Auscultation by 
vascular surgeons 
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Data Sources and Searches 
 The latest review examining the topic of screening for carotid bruit was conducted in 
1996. To ensure that I examined the updated literature since this review, I searched the 
MEDLINE literature for articles that were written in English that addressed my KQs. I looked 
for RCTs and cohort studies comparing screening for carotid bruit in asymptomatic adults to 
those not screened for carotid bruit or those found to possess a bruit compared to those without. I 
also searched for diagnostic accuracy studies comparing auscultation for carotid bruit to the 
reference standard of angiography. For the MEDLINE search I used the focused MeSH terms 
“Carotid Artery Stenosis,” “Carotid Artery Diseases,” and “bruit” yielding 216 results. I utilized 
the filters “Humans,” “English,” “Adult: 19+ years,” and also filtered by study type. This 
narrowed the results to 128 studies. Narrowing further to include only studies published since 
1996 limited this to 87 studies. I also augmented this search by hand-searching the reference lists 
of several relevant studies and review articles to find any other studies that met the inclusion 
criteria. 
Comparison Group Adults in the general population asymptomatic for stroke 
symptoms who are NOT screened for CAS by 
auscultation for carotid bruit or who are found to not 
have bruit on auscultation. 
 
Outcomes 1. Fatal or nonfatal ischemic stroke or TIA 
2. Carotid Artery Stenosis 
 
Time for Intervention 
to Work 
Follow-up of at least 24 months for stroke and/or TIA.  
Time period for 
relevant 
studies/literature 
Studies published since 1996 (year of previous USPSTF 
review examining auscultation for Carotid Bruit) 
Anything prior to 
1996 
Setting Studies conducted in developed countries defined as 
those with a “very high” human development index per 
the UN Development Program. (47 countries) 
http://hdr.undp.org/en/media/HDR_2011_EN_Table1.pdf  
All other countries 
Study Designs RCTs or cohort studies comparing screened vs. non-
screened groups; diagnostic accuracy studies that 
compared screening tests to gold standard(angiography) 
to evaluate effectiveness 
All other designs 
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Study Selection 
 I selected and reviewed the titles and abstracts of the articles that were retrieved for my 
KQ in a systematic manner using one reviewer. I utilized predetermined inclusion and exclusion 
criteria that were similar to those used in previous USPSTF reviews and are included in Table 1. 
For all included articles I then pulled the full texts and reviewed them based on the previously 
specified inclusion/exclusion criteria to ensure that they still met these criteria to be included. If 
not they were excluded as well. I identified one additional study that met inclusion criteria 
through my hand search of the reference lists of several relevant articles. To be included the 
studies had to be RCTs or cohort studies of asymptomatic patients at least 19 years of age, from 
which data on cerebrovascular outcomes could be extracted for KQ1. They could also be 
diagnostic accuracy studies comparing auscultation for carotid bruit to the gold standard of 
angiography in asymptomatic patients at least 19 years of age for KQ2. These studies had to be 
published in English. The study selection was done using a single reviewer method but would 
have entailed dual-review if more time and resources were available.      
Data Extraction and Quality Assessment 
 I reviewed the full-text articles for all the citations meeting the eligibility criteria and 
quality-rated them independently using a single reviewer method. Again, for the purpose of this 
review a single reviewer was sufficient. However, double review would have been utilized if 
more time and resources were available. Data extracted from the studies included the source 
population and comparison group(s); average age; sample size; average time of follow-up; 
sensitivity, specificity, and accuracy of detecting stroke, TIA, and stroke death; false-positive 
and false-negative rates; gold standard utilized for stenosis measurement; and overall 
conclusions from the studies. This extracted data is included in Table 2.  
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I attempted to follow the defined criteria specified in the USPSTF procedure manual to 
evaluate internal and external validity of the included studies and literature sources and apply a 
modified scoring method to grade the criteria for each study (38). For this grading I gave a score 
of 1-, 2-, or 3-plus (+) to each criteria of the study with 3-plus being the best or most positive 
rating. An overall quality assessment was formulated that takes into account the scoring for each 
criterion. Using this grading method, I evaluated the quality of RCTs and cohort studies based on 
the assembly and maintenance of comparable groups; level of differential and overall follow-up 
of subjects; equal, valid, reliable, and appropriate outcome measures; clearly defined 
screening/interventions; generalizability; and the validity of their conclusions. I evaluated 
diagnostic accuracy studies based on the adequate description of the screening test, use of a 
credible reference test, independent interpretation of the reference, handling of indeterminate 
results, sample size and spectrum of patients, generalizability, and the validity of their 
conclusions. These studies were all given a rating of “good,” “fair,” or “poor” based on the 
criteria presented in the USPSTF procedure manual and the definitions for these ratings which 
are also published (38). For the strength of evidence assessment I took into account both the 
certainty and the magnitude of effect for the results and conclusions from the included articles 
and rated it as either low, moderate, or high. I organized this information into a quality and 
strength of evidence table and it is displayed in Table 3.  
Data Synthesis and Analysis 
 I compiled all of the relevant data from the included studies quantitatively and 
qualitatively in a table and in narrative format. This is shown in Table 2. I organized the 
synthesized data for KQ1: What is the accuracy of auscultation for carotid bruit to predict fatal or 
nonfatal ischemic stroke or TIA? I also did this for the KQ2: What is the accuracy of auscultation 
for carotid bruit to detect potentially clinically important CAS (60% to 99%)?  I grouped the data by 
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those screened for bruit vs. not screened when applicable or by those found to have bruit vs. 
those without bruit.   
Role of Funding Source(s)  
 
I did not receive any specified funding for this particular review and there are no known 
conflicts of interest related to this. 
Table 2. Data Extraction Table 
 
KQ1: 
Study 
Refere
nce 
Study 
Design 
Source 
Population 
& 
Comparison 
Groups 
Sampl
e Size 
& 
Avg. 
Age 
Mean 
Follow-up 
time 
Sensitivi
ty, 
Specific
ity, & 
Accurac
y for 
stroke 
False 
Positiv
e & 
Negati
ve 
Rate 
for 
Stroke 
Sensitivi
ty, 
Specific
ity, & 
Accurac
y for 
TIA 
Sensitivi
ty, 
Specific
ity, & 
Accurac
y for 
stroke 
death 
Overall 
Conclusio
n(s)  
Gillett 
(2003) 
Prospect
ive 
Cohort 
(The 
Fremantl
e 
Diabetes 
Study) 
Australian 
community-
based 
sample of 
patients w/ 
type 2 
diabetes 
and no hx 
of 
cerebrovasc
ular 
disease; 
Comparison 
of those 
with carotid 
bruit to 
those 
without 
bruit. 
1181 
patien
ts; 64 
years 
6.5 years; 
7676.5 
patient-
years (344.5 
w/ bruit; 
7332 
without 
bruit)*calcul
ated using 
mean follow-
up time of 6.5 
years and 
sample size. 
Sens: 
13.4%; 
Spec: 
96.7%; 
Accy: 
87.2%  
FP: 
3.3%; 
FN: 
86.6% 
NR NR (25 
stroke 
deaths 
during 
follow-
up but 
not 
reported 
by bruit 
status) 
Type 2 
diabetic 
patients 
w/ 
incidental 
carotid 
bruits 
have > 6 
times risk 
of first 
stroke in 
first 2 
years 
compared 
to those 
without 
bruit and 
should 
receive 
intensified 
manageme
nt of 
vascular 
risk 
factors. 
No 
difference 
in risk 
beyond 
initial 2 
year 
period. 
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Shorr 
(1998) 
Prospect
ive 
Cohort 
(SHEP 
study) 
Asymptoma
tic Cohort 
from SHEP 
study ≥ 60 
years old w/ 
avg BP of 
160-
220/<90 
mm Hg. 
Comparison 
of those w/ 
Bruit to 
those w/out 
Bruit. 
4,442 
patien
ts; 
71.5 
years 
4.5 years; 
18,488 
patient-
years 
Sens: 
9.1%; 
Spec: 
93.75%; 
Accy: 
89.4% 
FP: 
6.25% 
FN: 
90.9% 
NR NR Carotid 
bruits in 
asymptom
atic 
elderly 
patients 
w/ 
isolated 
systolic 
hypertensi
on do not 
identify 
persons at 
greater 
risk of 
stroke. 
Small 
trend 
toward 
increased 
risk in 
patients 
aged  60-
69 years 
but not 
aged ≥70 
years 
 
KQ2: 
Study 
Reference 
Study 
Design 
Sample 
Size & 
Avg. 
Age 
Degree 
of 
Stenosis 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% 
CI) 
NPV 
(95% 
CI) 
Overall 
Accuracy 
(95% CI) 
Overall 
Conclusion 
NA * * * * * * * * * 
 
Table 3. Quality & Strength of Evidence Table 
 
 RCTs and Cohort Studies 
Study Assembly of 
Comparable 
Groups & 
Consideration 
of Confounders 
Maintenance 
of 
Comparable 
Groups 
Significant 
Loss to 
Follow-up 
Measurem
ents Equal, 
Valid, & 
Reliable 
Clear 
definition of 
Screening tool 
used 
Considers 
Relevant 
Outcomes 
(Stroke/TIA) 
Generalizabi
lity 
Strength 
of 
Evidence 
(High, 
Moderate
, Low) 
Qualit
y 
(Good
, Fair, 
Poor) 
Gillett 
(2003) 
++ ++ +++ +++ ++ ++ ++ Moderate Good 
Shorr 
(1998) 
++ +++ +++ ++ ++ ++ ++ Low  Fair 
 Diagnostic Accuracy Studies  
Study Screening Test 
Adequately 
Described 
Credible 
Reference 
Standard used 
Reference Standard 
Interpreted 
Independently  
Handling of 
Indeterminate 
Results 
Sample Size & 
Spectrum of 
Patients 
General
izability 
Strength of 
Evidence 
Qualit
y 
N/A * * * * * * * * 
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Results: 
Search Results 
 The initial MEDLINE search yielded 216 results. After applying the filters “Humans,” 
“English,” “Adult: 19+ years,” and also filtering by study type, this left me with 128 results. Out 
of these, 87 articles were published within the target time frame of 1996 to present. Through title 
and abstract review of these articles, I selected 12 articles for full-text review. At the full-text 
review stage I excluded 11 of these articles, mostly due to wrong population, wrong intervention, 
wrong comparison group, or wrong outcomes reported. I identified one additional article for 
inclusion through hand-searching the reference lists of other relevant articles, thus resulting in 2 
articles for inclusion for KQ1. The study selection strategy used is demonstrated with a flow 
chart shown in figure 3.  
Figure 3. Search Inclusion/Exclusion Flowchart 
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There were no RCTs meeting inclusion for KQ1 that directly compare a cohort of 
patients screened for carotid bruit to those not screened. One good quality and one fair quality 
prospective cohort study were included comparing patients with and without carotid bruit. One 
fair to good quality systematic review/meta-analysis was also identified that evaluated a subset 
of studies directly comparing outcomes in patients with a carotid bruit to those of patients found 
to lack a carotid bruit after screening by auscultation. This systematic review includes in its 
analysis the 2 cohort studies that met my inclusion criteria. Due to this it is not included in my 
analysis, but the findings are discussed in the discussion section.  
There were no included studies for KQ2 as I was unable to identify any meeting criteria 
that used angiography as the gold standard for measurement of degree of stenosis. Because of 
this, I went back and identified studies from my search that met inclusion except for their use of 
duplex ultrasound instead of angiography as the reference standard. Based on this, I identified 2 
studies and a systematic review for discussion of KQ2. Because these studies did not originally 
meet inclusion criteria, I excluded them from any formal analysis for KQ2 but discussed their 
results in the discussion section, similar to the approach taken for the systematic review for KQ1.    
Summary of Study Results 
Key Question 1: What is the accuracy of auscultation for carotid bruit to predict fatal or 
nonfatal ischemic stroke or TIA? 
 
 Two prospective cohort studies were identified and included for KQ1 that provided data 
on the accuracy of auscultation for carotid bruit for predicting ischemic stroke. Neither of these 
studies reported data for TIA or stroke death that could be used to calculate sensitivity, 
specificity, or overall accuracy for these events/outcomes. These two studies of fair to good 
quality for KQ1 provide a sensitivity range of 9.1%-13.4% and a specificity range of 93.75%-
96.7% (32, 39). Crudely averaging the values from these studies gives a sensitivity of 11.25% 
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and specificity of 95.2% for the accuracy of auscultation for carotid bruit to predict future stroke 
based on bruit status. 
The first study, Gillett et al. published in 2003, looked at a subset of 1181 patients from 
the Fremantle Diabetes Study which used a community-based sample of 1294 patients in 
Western Australia with type-2 diabetes and no history of cerebrovascular disease (39). The 
average age of the study patients was 64 years and the mean follow-up time was 6.5 years or 
7676.5 patient-years. The study compared the patients in the community cohort found to have a 
carotid bruit to those without a carotid bruit. Based on the data provided, I was able to calculate 
sensitivities, specificities, and accuracy for predicting those who will suffer a stroke over an 
average of 6.5 years. I also used this to calculate prevalence of stroke in the population, positive 
predictive value, negative predictive value, false-positive rate, and false-negative rate. The 
sensitivity, specificity, and accuracy of auscultation for carotid bruit to predict stroke were 
13.4%, 96.7%, and 87.2% respectively (39). There were 134 first strokes during follow-up with 
18 in patients with carotid bruit and 116 in those without. Of those patients who did not suffer a 
stroke, 35 possessed a bruit and 1012 did not. The prevalence of stroke in the study participants 
was 11.3%. Positive and negative predictive values were 34% and 89.7%, while the false-
positive and false-negative rates were 3.3% and 86.6% respectively (39). Data for the outcome of 
TIA was not reported. Also the authors state that 25 stroke deaths occurred during follow-up but 
they do not report this outcome by carotid bruit status. Thus relevant accuracy data for this 
outcome could not be determined. The authors concluded that type 2 diabetic patients who are 
found to have incidental carotid bruits have more than six times the risk of suffering a first stroke 
in the first two years of detection compared to those without a carotid bruit and they should 
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receive more intensified management of vascular risk factors. Beyond the initial two year period 
they found no difference in risk between these groups (39). 
The other included study, Shorr et al. published in 1998, looked at a subset of 4442 
patients from the original 4736 participants in the Systolic Hypertension in the Elderly Program 
(SHEP) who had no history of cerebrovascular disease symptoms or myocardial infarction (32). 
All of these patients were at least 60 years old with isolated systolic hypertension, having an 
average blood pressure of 160-220/<90 mm Hg. The average age of included patients was 71.5 
years and the mean follow-up time was 4.5 years or 18,488 patient-years. Like the other included 
study, this one compared a cohort of patients with a carotid bruit to those without a bruit. Over 
an average follow-up time of 4.5 years the calculated sensitivity, specificity, and accuracy of 
auscultation for carotid bruit to predict stroke were 9.1%, 93.75%, and 89.4% respectively (32). 
During follow-up 231 strokes occurred, 21 of which happened in patients with a carotid bruit and 
210 in those without a bruit. Out of the patients who did not suffer a stroke, 263 possessed a 
carotid bruit compared to 3948 without bruit. The prevalence of stroke was 5.2% with positive 
and negative predictive values of 7.4% and 94.9% respectively. There was a false-positive rate of 
6.25% and false-negative rate of 90.9% (32). This study, like the other one, did not report similar 
data for the outcomes of TIA and stroke death and thus the accuracy for these other outcomes 
remains unclear based on this more recent evidence. The authors of this study concluded that 
carotid bruits found in asymptomatic elderly patients with isolated systolic hypertension do not 
identify persons at greater risk of stroke. They did note a small trend toward increased risk in 
patients of age 60-69 years but not in those at least 70 years old (32).   
The systematic review/meta-analysis I identified for KQ1 was published in 2010 and it 
included 28 prospective cohort studies following a total of 17,913 patients for 67,708 patient-
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years (40). The mean age of patients was 64.8 years with a range of 60 to 71.6 years. The authors 
looked at the relevant outcomes of TIA, stroke, and stroke death and limited their inclusion 
criteria to prospective cohort studies performed in asymptomatic adults (40). However, they did 
not provide data in terms of sensitivity, specificity, and overall accuracy. Instead the authors 
provided pooled rate ratios for those with carotid bruits compared to those without. There were 5 
studies that investigated the outcome of TIA and provided head-to-head comparisons for those 
with and without bruits. The pooled risk ratio for suffering a TIA in patients with carotid bruit 
compared to those without was 4.00 (1.77-9.03). There were 6 studies providing direct 
comparison of these two patient groups for the outcome of stroke. The pooled risk ratio for 
suffering a stroke was 2.49 (1.77-3.52). This pooled data took into account the two included 
studies for KQ1 of my current review which gave stroke rate ratios of 3.18 and 1.46 respectively 
(32, 39). For stroke death there were 3 studies that provided direct comparison of the two patient 
groups giving a pooled risk ratio of 2.71 (1.33-5.53). The authors of this review/meta-analysis 
concluded that patients who possess a carotid bruit have more than 4 times the risk of TIA and 
more than 2 times the risk of stroke and death from stroke compared to patient controls without 
carotid bruits (40).  
Key Question 2: What is the accuracy of auscultation for carotid bruit to detect potentially 
clinically important CAS (60% to 99%)? 
 
 There were no studies found that addressed this question using the proper gold standard 
of angiography. However, I identified 2 cohort studies that would have otherwise met inclusion 
as well as a systematic review that all use the gold standard of duplex ultrasound to look at this 
question. The findings and conclusions of these studies, though not included for formal analysis 
of KQ2, are presented here and further examined in the discussion section.  
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 The first cohort study, published in 2009, looked at a subset of multiethnic community-
based patients from the Northern Manhattan Study (NOMAS) who were asymptomatic and with 
no history of cerebrovascular disease (41). This entailed 686 of the original 3298 NOMAS 
patients making up the stroke-free cohort who were auscultated for carotid bruit by neurologists 
and also received duplex ultrasonography of the carotid arteries. Approximately 9% of these 
patients or 61 had a history of coronary artery disease which was defined as a prior history of 
MI, CABG, or angioplasty (41). These patients were not separated out in the analysis, but 
because they made up such a small percentage of the included patients, the data is still mostly 
representative of asymptomatic patients as defined by my inclusion criteria. The average age of 
the included patients was 68.2 years with a range of 40-96 years. The racial make-up was 58% 
Hispanic, 21% African-American, and 19% Caucasian. Both carotid artery sides were examined 
for each patient accounting for 1372 arteries for analysis. A carotid bruit was detected in 28 
subjects with 8 being bilateral, thus accounting for 36 arteries with bruits while 1336 were 
without bruit (41). The prevalence of bruit in the study population was 4.1% and that of CAS ≥ 
60% detected by duplex ultrasound was 2.2%. The sensitivity, specificity, and accuracy of 
auscultation for carotid bruit to detect ipsilateral CAS ≥ 60% were 56.25%, 98%, and 97.5% 
respectively. The positive and negative predictive values were 25% and 99%, while the false-
positive and false-negative rates were 2% and 43.75% respectively (41). The authors concluded 
that a carotid bruit heard on physical exam should prompt further evaluation with carotid duplex 
ultrasound; however, with its low sensitivity and positive predictive value combined with its 
false-negative rate, bruit auscultation is not adequate for excluding CAS ≥ 60% (41).  
The other cohort study using ultrasound as the reference standard was published in 2007 
and investigated the accuracy of the screening physical exam to identify CAS in a subset of 
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asymptomatic French patients from the Evaluation du Dépistage de la Coronaropathie 
(EVADEC) study (42). This study looked at 2736 asymptomatic French patients with a mean age 
of 52.3 years and a range of 20-90 years. The authors were investigating not only carotid bruits 
and their ability to identify CAS but also femoral bruit and its ability to identify femoral plaque 
and lower limb atherosclerosis as physicians in practice usually auscultate and palpate both of 
these arteries to assess atherosclerosis during a full vascular physical exam. For CAS accuracy 
determination the study used CAS > 50% identified on ultrasound as its cutoff. There were 106 
patients with carotid bruits in the study population giving a prevalence of 3.9%. The prevalence 
of CAS > 50% in the population was 4.2% as 114 patients were found to possess this (42). 
Sensitivity, specificity, and accuracy measures were not provided from this study, yet it does 
provide positive and negative likelihood ratio calculations (LR+ & -) for the ability of 
auscultation for carotid bruit to detect ipsilateral CAS > 50%. The necessary data to calculate 
sensitivity, specificity, and accuracy were not provided within the study, specifically the 
numbers of patients with and without bruits who possessed or did not possess CAS > 50%. 
However, the LRs include sensitivity and specificity in their calculation and thus can be 
considered meaningful data for investigation of accuracy. The LR+ and 95% confidence interval 
for detection of carotid bruit in patients with ipsilateral CAS > 50% was 0.90 (0.34-2.41). The 
LR– and 95% confidence interval was 1.00 (0.97-1.04) (42). The authors concluded that the 
presence of a carotid bruit did not affect the likelihood of carotid stenosis and carotid 
auscultation does not seem to provide strong predictive information on underlying 
atherosclerosis (42).  
I identified one recent systematic review/meta-analysis published in 2012 that also 
attempted to evaluate the accuracy of carotid bruit to detect various levels of CAS (43). The 
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meta-analysis included 26 studies looking at a total of 15,117 carotid arteries, 3502 with bruits 
and 11,615 without bruits (43). In the meta-analysis they classified degree of stenosis into 
several categories. A total of 12 studies in the analysis looked at CAS ≥ 50% for a pooled 
sensitivity and specificity of 55.8% and 82% respectively. The false-positive and negative rates 
are 18% and 44.2%. There were 7 studies that used a CAS cutoff of ≥ 60% and they yielded a 
pooled sensitivity and specificity of 57.5% and 80% respectively. The false-positive and negative 
rates were 20% and 42.5% respectively. For CAS ≥ 70% there were 6 studies giving a pooled 
sensitivity and specificity of 43.9% and 86% respectively with false-positive and negative rates 
of 14% and 56.1% (43). Finally the authors defined a group as clinically relevant stenosis which 
included CAS ≥ 70%, ≥ 75%, and ≥ 80%. A total of 12 studies looked at this category giving a 
pooled sensitivity and specificity of 53% and 83% respectively with false-positive and negative 
rates of 17% and 47% (43). The authors concluded that routine examination for carotid bruit in 
clinical practice is of moderate value for detecting CAS as it has high specificity but low 
sensitivity. The absence of bruit cannot reliably rule out the presence of CAS (43). 
Discussion: 
 In the last evidence review and recommendation update by the USPSTF analyzing 
auscultation for carotid bruit as a CAS screening tool in 1996, they determined that there was 
insufficient evidence to recommend for or against screening asymptomatic people for CAS using 
this means during physical exam (10). This was based on current evidence at the time that risk of 
major stroke in asymptomatic patients due to CAS is low without surgery at approximately 1% 
per year, there was small absolute risk reduction in stroke and death from surgery over 5 years in 
the ACAS, and the fact that the low complication rates of surgeons in the ACAS of < 3% are 
unlikely to be representative of rates for endarterectomy performed in the community setting 
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(10). Therefore it could not be determined if the benefits outweigh the risks for widespread 
screening. In their review they also looked at the accuracy of auscultation for bruit in identifying 
clinically significant CAS. Using the reference standard of 70-99% stenosis on carotid 
angiogram, the sensitivity and specificity of a carotid bruit was determined to be 63-76% and 61-
76% respectively (10, 44). Comparatively, duplex ultrasound was found to have a sensitivity of 
83-86% and specificity of 89-94% (10, 45) They did not provide sensitivity and specificity 
measures for the ability of auscultation for carotid bruit to determine those asymptomatic 
patients with no previous stroke or TIA who will suffer a stroke or cerebrovascular outcome, but 
found the annual incidence of stroke ipsilateral to bruit to be 1-3% in these patients (10, 31, 35, 
46).     
 Since the publication of the 1996 recommendation as well as the 2007 update, very few 
studies have been published that investigate the accuracy of auscultation for carotid bruit as a 
screening tool for predicting stroke outcomes as well as clinically significant CAS in 
asymptomatic patients utilizing a reference standard of angiography. For KQ1 the 2 included 
studies provided a sensitivity range of 9.1%-13.4% and a specificity range of 93.75%-96.7% or a 
crude average of 11.25% and 95.2% respectively for identifying stroke while that for the 
outcomes of TIA and stroke death remains unclear (32, 39). The systematic review for KQ1 
contributed nothing more to these accuracy measures but found that patients with carotid bruits 
have 4 times the pooled risk of TIA and over 2 times the risk for both stroke and stroke death 
compared to those lacking bruits (40). 
 For KQ2 there were no studies that originally met inclusion, yet two cohort studies and a 
systematic review on the topic using duplex ultrasound as the reference standard were identified 
for discussion. These studies show that, though the specificity is reasonably higher compared to 
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the sensitivity values of auscultation for bruit with a range of 80-98% versus 56.25-57.5% for 
CAS ≥ 60%, both the sensitivity and specificity are poor and not adequate for a screening test. 
The LRs for identifying CAS ≥ 50% with this test were also both very close to 1, indicating that 
the test results show little to no association with CAS. 
 The most significant weaknesses and limitations of my study arise from those of the 
included studies themselves and the subsequent level of certainty of my results. Because my 
results were based on so few studies, most of which were graded as fair quality, the level of 
certainty for my findings is low to fair at best. For KQ1, both the cohort studies did a fair job 
compiling and maintaining comparable groups, though some differences did exist between those 
with bruits compared to those lacking them. These included slightly older age, higher total 
cholesterol, increased systolic BP, and higher rates of hypertension in those with bruits for both 
of the studies. This leaves potential for confounding due to more poor health states in the bruit 
groups. I deemed the strength of evidence to be low to moderate at most. This was mostly related 
to the level of certainty of the accuracy measures as the studies themselves did not provide 
sensitivity and specificity values. Instead, I attempted to calculate these by hand using relevant 
pieces of data within the study. These values could differ to some degree if there is other 
necessary data that was not included or clearly denoted within the published studies themselves. 
Also they did not provide evidence for the outcome of TIA in addition to stroke, which further 
limits the strength of evidence for my KQ. Additionally, generalizing the results to a largely 
healthy asymptomatic population is somewhat problematic because of the study populations used 
in both of these studies. All of the patients in the first study were type-2 diabetics while those in 
the other study were all non-institutionalized elderly at least 60 years old with isolated systolic 
hypertension (32, 39). In the Shorr et al. study the population was a highly selected one of 
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elderly hypertensive patients representing only 1% of those initially screened making 
generalizability of the findings even to other elderly hypertensive populations somewhat 
precarious. As diabetes, increased age, and hypertension have all been linked to increased risk 
for CAS and subsequently stroke, studying the accuracy of a screening test to identify these 
outcomes in populations solely made up of patients with these risk factors may actually confound 
the results due to a greater number of CAS cases and stroke outcomes occurring in these 
populations (25, 27).  
In the systematic review/meta-analysis identified for KQ1 several of the included studies 
were not very recent, with years dating back to the late ‘70s and early ‘80s. The results from 
these older studies could bias the rate results of the pooled analysis for relevant outcomes as it is 
likely that more recent changes in medical management may have altered the prognosis of 
patients with bruits. The inclusion of these less recent studies was the most limiting factor 
affecting the quality of this review. There was also a high amount of heterogeneity between the 
studies and their results, especially in terms of the included study populations and reporting of 
potential confounding factors such as prevalence of hypertension or diabetes between groups 
(40). Though this study’s results provide fair evidence that patients found to possess carotid 
bruits are at greater risk of suffering poor cerebrovascular outcomes than those lacking bruits, 
this tells us little about how accurate auscultation for carotid bruit is as a screening test to detect 
those who will suffer these bad cerebrovascular outcomes. 
For KQ2 the greatest weakness in all of the studies comes from their use of duplex 
ultrasound as the reference standard for stenosis calculations instead of the true gold standard of 
angiography which is a much more accurate test for identifying degree of stenosis. However, the 
risk of harmful outcomes such as stroke that arise from invasive testing like angiography makes 
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it difficult to ethically subject such asymptomatic patients to this invasive testing. The use of 
non-invasive tests like ultrasound which have very little risk of harmful outcomes from the 
testing itself are much easier to justify in such studies and still provide meaningful data on the 
accuracy of carotid bruits for identifying significant degrees of CAS.  
The two cohort studies were graded good and fair quality respectively while the 
systematic review was poor. The Ratchford et al. study provided comparable groups of patients 
with and without bruits with the most significant difference arising in average age of the groups. 
That of patients with bruits was higher at 75.1 years compared to 67.9 years for those without 
bruit (41). The fair quality cohort study by Cournot et al., unlike the other study, did not provide 
comparable groups separated by carotid bruit status. Instead they grouped patients by having a 
normal versus abnormal vascular physical examination that took into account not only presence 
or absence of carotid bruits but also presence or absence of various lower limb pulses. They also 
did not provide a distribution of various risk factors such as smoking and diabetes by groups of 
patients with carotid bruits versus those without. Therefore it is difficult to assess the potential 
for confounding from these variables. In the same study the vascular physical exam was 
performed in all patients by one specially trained study physician who was a preventive 
cardiologist. Because the study physician was specially trained in auscultation of carotid bruit for 
this study, the ability of this physician to detect bruit compared to that of physicians in an 
average community primary care setting may be different. Thus this could affect the 
generalizability of this study to the community setting, although likely very minimally. Though 
the first cohort study’s results are generalizable to other multiethnic community populations in 
the US as Manhattan provides a very diverse, yet representative subset of the country’s general 
population make-up, the generalizability of the Cournot et al. study to a US community is likely 
Watford 33 
 
lower as it was carried out only in French patients. Though this study considers the relevant 
outcome of CAS > 50% ipsilateral to carotid bruit, it would have provided a much better 
assessment of accuracy if they included sensitivity and specificity calculations based on bruit 
status instead of solely giving likelihood ratios. Also these numbers would have been much 
easier to compare across other studies as these are the most commonly used measures to assess 
accuracy of screening tests (47). 
The systematic review by McColgan et al. for KQ2 was poor, mostly due to the fact that 
the included studies did not limit their populations to only asymptomatic patients. Instead they 
included all populations of patients such as those with coronary artery diseases or those 
scheduled to undergo CABG. Very few of the included studies only looked at asymptomatic 
patients. This makes it quite difficult to generalize their findings and conclusions to an 
asymptomatic population with no previous history of poor cerebrovascular/cardiovascular 
outcomes. Also, like the review for KQ1, several of the included studies are not recent and the 
data is likely outdated to some degree: one of the studies dates back to 1975 and most of the 
others were published in the 1980s to early 1990s. The authors actually reported study quality as 
weak in 22 of the included 26 studies, mostly because of lack of blinding and potential for 
publication bias (43). There was significant heterogeneity between the included studies for all the 
categories of CAS including wide variation in the imaging techniques used to assess degree of 
CAS. Only one study actually reported using NASCET or ESCT criteria to define stenosis and 
this study was carried out in patients scheduled for coronary artery bypass (48). It was also 
carried out in a country that does not meet the setting criteria for this review, further affecting 
generalizability. Finally, they looked at 12 studies investigating their category of clinically 
relevant stenosis (≥70%, ≥75%, and ≥80%). However, only 2 of these 12 studies investigated 
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asymptomatic bruits and subgroup analysis for asymptomatic bruits was not performed due to 
the low number of studies (43). Again this greatly brings into question the validity and 
generalizability of these results for an asymptomatic population. 
For KQ1, although the specificity determined from the two cohort studies seems to be a 
high value as it sits above the 90% threshold, specificities for screening tests must generally be 
98-99% to be considered adequately accurate (47). When screening a population the expectation 
is generally that the prevalence of what you’re screening for is low and that the vast majority of 
people screened will not possess the disorder in question. So by only identifying 95% of this 
huge number of people who do not have the disorder, you are still left with the remaining 5%. 
Subsequently 5% of this huge number is still a huge number thus leaving you with a ton of false-
positive results. Therefore this specificity falls short and the sensitivity is also very low for 
identifying the outcome of stroke. These values are certainly not adequate for a screening test. 
Such a test would lead to false-positives nearly 5% of the time and would produce a false-
negative result nearly 89% of the time. Based on this, screening for carotid bruit would falsely 
identify many patients believed to be at greater risk for stroke who actually are not and also fail 
to identify a huge amount of patients who will go on to suffer a stroke over the next 5.5 years 
approximately. If the aim of a CAS screening test is to accurately identify those at increased risk 
of future stroke in order to prevent this outcome, the use of auscultation for carotid bruit would 
present much difficulty in sufficiently satisfying this objective.  
Though the cohort studies for discussion of KQ2 provide different measures of accuracy 
in their use of sensitivity and specificity versus likelihood ratios and use different CAS cutoff 
points, in combination with the systematic review they point to similar conclusions with regard 
to accuracy of auscultation for carotid bruit as a screening test. Based on the results, both the 
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sensitivity and specificity are poor and not adequate for a screening test as was the case for KQ1. 
These accuracy values lead to a very weak ability to rule out as well as rule in clinically 
significant CAS ≥ 60% with tests yielding false-negative results more than 40% of the time and 
false-positive results as much as 20% of the time. This would cause a substantial amount of 
screened people to not receive confirmatory testing and potentially necessary treatment for CAS 
that they are made to believe they do not possess based on the wrong results from their screening 
test. A portion of these patients would suffer strokes or TIAs that could have been avoided had 
they received proper preventative treatment such as CEA or CAAS. On the other side of this 
scenario screening would also cause a considerable amount of people to be subjected to further 
confirmatory testing that may be harmful, anxiety, and even unnecessary and harmful treatment 
for CAS that was actually not present.  
Also the LRs for identifying CAS ≥ 50% with this test were both very close to 1, 
indicating that the test results show little to no association with CAS. Thus the test as a screening 
tool would not yield a significant difference between the pre-test and post-test probabilities of 
CAS and should have little effect on clinical decision making, especially in the case of a negative 
test result. Because these studies rely on the use of an imperfect reference standard in duplex 
ultrasound, the accuracy measures may actually be underestimated compared to the true accuracy 
of the test. However, based on the results of two meta-analyses examining the accuracy of 
ultrasound compared to angiography, it seems very unlikely that the use of ultrasound as a 
reference would account for more than just a slight difference of a few percentage points in 
accuracy measurements (49, 50). Therefore, I would expect any underestimation to only be to a 
small degree and not account for a large enough difference in sensitivity to change the 
conclusion about the accuracy of auscultation for carotid bruit. Therefore the implications from 
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the studies for both KQ1 and KQ2 are that auscultation for carotid bruit has less than adequate 
accuracy as a screening test for CAS and stroke outcomes and should not be used for this 
purpose when just considering its accuracy. However, it is important to keep in mind that the 
level of certainty of the findings is only fair at best.      
Yet when determining whether a test should be used for screening, sensitivity and 
specificity are not the only aspects that are important for consideration. This is especially the 
case when screening for specific levels of CAS. Sensitivity and specificity only tells us how 
much CAS we can find and whether or not we are labeling too many people through false-
positives or negatives. However, they don’t tell us if we’re finding the right people that we are 
looking for. What we are most concerned with is preventing stroke outcomes in patients with 
CAS and these depend on much more than solely the level of CAS a patient possesses. Clearly 
all patients who possess CAS ≥ 60% do not suffer a stroke and experiencing this outcome 
depends on whether the carotid plaque is unstable and ruptures and also on a multitude of other 
risk factors specific to the patient. We need to better understand which patients with CAS ≥ 60% 
will go on to suffer a stroke. What we would really like to have is a reliable means to risk stratify 
these patients in the general population and separate out only those for screening who are most 
likely to suffer stroke outcomes from CAS. In this scenario, the sensitivity and specificity values 
may actually be adequate because we could be somewhat certain that we are screening the right 
people, those most likely to be affected by stroke from CAS. Unfortunately we are currently 
unable to do this in a reliable manner using available risk assessment tools. Until such risk 
stratification is available we must consider screening in the entire general population. This 
review shows, with only fair certainty, that such screening is inaccurate.  
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However, this analysis evaluating the accuracy of this specific screening test only 
represents the first step in evaluation of an entire screening program for CAS. Though the results 
of this review show me with fair certainty that this individual test may be inaccurate for 
identifying clinically significant CAS and strokes in the general asymptomatic population, 
further investigation remains to be done to fully elucidate the usefulness of this specific 
screening test for identifying bruits within the greater screening program for CAS. As past 
studies have alluded to, it may even be that assessing for carotid bruits is most useful for 
determining general atherosclerotic burden in a patient that could lead to various other poor 
cardiovascular outcomes beyond stroke, such as myocardial infarction (7, 9, 39). Though 
screening for bruits in this context may not lead to reduced strokes, it may serve as a tool for 
physicians to better assess their patient’s cardiovascular risk level in general. However, this still 
remains to be shown with strong certainty.       
Research Gaps & Future Directions 
 The most obvious gap in research pertaining to the topic of screening for CAS using 
auscultation for carotid bruit is the lack of any RCTs directly comparing a cohort of patients 
screened for carotid bruit to those not screened to determine if this results in reduced 
cerebrovascular outcomes. These high-quality study types provide much better linkages to 
causation and also are less vulnerable to potential biases that arise due to lack of blinding of 
information from both researchers and patients throughout the study (51). Future RCTs 
investigating screening for CAS could take us beyond just accuracy of auscultation for bruit as a 
screening test. These studies could help give meaningful conclusions about whether screening 
for CAS in this way actually causes lower rates of stroke and stroke outcomes in the population. 
Yet this specific screening test is only the initial step in a whole screening program that 
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encompasses a treatment protocol. This ultimately leads to CEA or CAAS to prevent stroke as 
shown in figure 2. The evidence on benefits as well as risks of harm from these treatments is still 
very uncertain in the general community. In the future we must continue to better delineate these 
risks to fully understand the benefit that can arise through screening for CAS.  
 Also future studies examining the accuracy of auscultation for carotid bruit to identify 
various degrees of clinically relevant CAS based on the correct reference standard of 
angiography are necessary to further elucidate the true accuracy of this screening test for 
identifying CAS. The lack of recent publication of such studies led to my inability to identify any 
studies for inclusion addressing KQ2. This dearth of such studies is likely due to the fact that 
intra-arterial carotid angiography carries risks of micro-emboli and strokes itself, with an 
estimated risk for major stroke of 1% (52). Currently less invasive angiographic techniques are 
being employed more frequently such as magnetic resonance angiography (MRA) and computed 
tomography angiography with reasonable accuracy when compared to conventional angiography 
(53, 54). However, these tests are quite expensive, are not 100% accurate, and carry some risks 
for neurovascular events as well. Even more often physicians and researchers are utilizing the 
noninvasive tool of duplex ultrasound both to assess CAS in practice as well as a reference 
standard in studies of screening accuracy, as was the case in the studies discussed above for 
KQ2.  
Still conventional angiography has 100% accuracy and remains the proper gold standard 
by which to judge accuracy of other CAS screening tests, especially considering the 
consequences of false-positives and negatives in screening protocols. Yet, because of the risks of 
this invasive testing, it is difficult to ethically justify subjecting asymptomatic patients with no 
previous history of cerebrovascular events to such a test that could lead to stroke or other poor 
Watford 39 
 
outcomes for the purpose of a study. Therefore most studies utilizing this reference standard 
have been performed in patients undergoing revascularization procedures or those who possess 
symptomatic CAS. Overcoming this ethical dilemma and gaining institutional review board 
(IRB) approval for such a study assessing accuracy of carotid bruit auscultation for detecting 
CAS in asymptomatic patients using the proper reference of conventional angiography will likely 
continue to be a difficult problem going forward. Nevertheless this type of high quality study is 
necessary if we wish to gain updated evidence to truly establish the accuracy of auscultation for 
carotid bruit as a screening test for identifying CAS.   
Conclusion 
The results from the studies discussed in this systematic review show with low to fair 
certainty that auscultation for carotid bruit has poor accuracy as a screening test in asymptomatic 
patients both for identifying CAS ≥ 60% as well as identifying those who will suffer a 
subsequent ischemic stroke. For KQ1 and KQ2, both the sensitivities and specificities were 
inadequate for a good screening test in the general population, with the sensitivity being 
especially poor concerning the test’s ability to identify those who will suffer the future health 
outcome of stroke. Though the included studies for KQ1 did not provide accuracy measures for 
the outcome of TIA, the systematic review showed a risk ratio of 4.00 for this outcome in 
patients with bruits compared to those without. Yet just showing that those patients with carotid 
bruits are at increased risk of stroke and TIA compared to their counterparts without bruits does 
not mean that this constitutes an accurate screening test for these cerebrovascular outcomes in 
the population. For KQ2 the sensitivity was slightly lower and the specificity slightly higher for 
identifying CAS than what the USPSTF determined in their last evidence review analyzing this 
screening test. Yet this was based on a reference of 70-99% on angiogram compared to that of 
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60-99% on ultrasound, which may account for some of this difference. Nonetheless these values 
were relatively close and the conclusion remains the same. I can say with fair certainty that the 
sensitivity and specificity along with the resulting false-positive and false-negative rates of this 
test are too poor for it to serve as a good screening tool in the general asymptomatic population. 
The presence of a carotid bruit on auscultation would do a poor job identifying only those 
patients in the population who possess CAS ≥ 60% as well as those who will suffer a subsequent 
stroke and would benefit from treatment due to the high rate of false-positives. At the same time 
the absence of a carotid bruit on auscultation would poorly exclude only those patients who do 
not actually possess CAS ≥ 60% as well as those who will not suffer a subsequent stroke due to 
the really high rate of false-negatives.  
Beyond just these accuracy measures for this specific screening test, we do not even have 
good evidence that applying a screening program actually reduces strokes in the population. This 
is in combination with the fact that we also do not know how to reliably determine which 
patients with clinically relevant CAS will actually suffer a stroke, providing a better pool to 
screen within. There have been no RCTs that directly compare a cohort of asymptomatic patients 
screened for carotid bruit to those not screened to assess if screening leads to less strokes and 
poor cerebrovascular outcomes. If we do not know with good certainty that using this screening 
tool will reduce cerebrovascular outcomes in our patients, then we should not utilize it in the 
population. This is regardless of the accuracy of the specific test as all testing and subsequent 
treatment presents various harms to the patient. These harms must be justified against the benefit 
that we get from screening. Without good understanding of the benefits from screening and what 
constitutes the best population to screen within, this justification cannot be well reconciled and 
we should not subject the general population to screening. Therefore because of inadequate 
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certainty of the benefit of screening for CAS in the general asymptomatic population, lack of a 
reliable means to delineate a more distinct group to screen in, and the poor accuracy of 
auscultation for carotid bruit in the primary care setting; I recommend against the use of this test 
to screen for CAS and future cerebrovascular outcomes as part of an overarching screening 
program aimed at reducing poor cerebrovascular outcomes.  
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